PANKAJ KUMAR

Dr. PANKAJ KUMAR

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
ARArunraj Tharamelveliyil Rajendran
Arunraj Tharamelveliyil Rajendran
GRGupta Dheeraj Rajesh
Gupta Dheeraj Rajesh
PKPANKAJ KUMAR
PANKAJ KUMAR
PDPrarambh SR Dwivedi
Prarambh SR Dwivedi
CSChakrakodi Shashidhara Shastry
Chakrakodi Shashidhara Shastry
Anoop Narayanan VAnoop Narayanan V
Anoop Narayanan V
Glioblastoma (GBM), the most prevalent brain tumor, is one of the least treatable malignancies due to its propensity for intracranial spread, high proliferative potential, and innate resistance to radiation and chemotherapy. Current GBM therapy is limited due to unfavorable, non-specific therapeutic effects in healthy cells and the difficulty of small molecules to penetrate the blood brain barrier (BBB) and reach the tumor microenvironment. Adding PARP-1 inhibitors inhibit DNA repair enzymes thereby increasing the cytotoxicity of anticancer agents. Hence, we aimed to discover potential naturally occurring PARP-1 inhibitors that can be utilized in the treatment of glioma by using multiple in silico tools like molecular docking, absorption, distribution, metabolism, and excretion (ADME) profile, pharmacophore modeling, and molecular dynamic (MD) simulations. Among 43 phytocompounds we screened, two of them (Ellagic acid and Naringin) were discovered to be bound to the catalytic site of PARP-1 with an affinity more remarkable than commercially available PARP-1 inhibitors (Talazoparib, Niraparib, and Rucaparib) except Olaparib. The molecular interactions were analyzed, and data shows that bound entity attained a conserved domain via hydrogen bond interactions, polar interactions, and π-π stacking. Pharmacophore modeling studies showed electronic and steric features of ligands responsible for supramolecular interaction with PARP-1. ADME properties were studied, to assess drug-likeness, hydrophilic nature, hydrophobicity, brain permeability, and oral bioavailability of the natural PARP-1 inhibitors. The simulation study demonstrated the development of a stable complex between Naringin, Ellagic acid, and PARP-1 protein. Moreover, cell culture studies and animal investigations are essential to determine pharmacokinetics and pharmacodynamics.

9 January 2025 in Peptide Science
Verified
Journal Article
Closed access
GRGupta Dheeraj Rajesh
Gupta Dheeraj Rajesh
KAKavita Apte
Kavita Apte
PAP. V. Abhirami
P. V. Abhirami
SAS. Anusha
S. Anusha
ARA. Ranjitha
A. Ranjitha
PKPANKAJ KUMAR
PANKAJ KUMAR

1 June 2023 in Annals of Phytomedicine An International Journal
Verified
Journal Article
Closed access
GDGupta Dheeraj
Gupta Dheeraj
PKPANKAJ KUMAR
PANKAJ KUMAR
KAKavita Apte
Kavita Apte
HAHarsha Ashtekar
Harsha Ashtekar
SDSeshagiri R Dixit
Seshagiri R Dixit


1 June 2024 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
NMN. V. L. Sirisha Mulukuri
N. V. L. Sirisha Mulukuri
Sujeet KumarSujeet Kumar
Sujeet Kumar
MDMoumita College of Pharmaceutical Dhara
Moumita College of Pharmaceutical Dhara
GRGupta Dheeraj Rajesh
Gupta Dheeraj Rajesh
PKPANKAJ KUMAR
PANKAJ KUMAR
Andrographolide is a natural diterpene lactone with multiple biological effects. In the present study, a total of 11 andrographolide-loaded emulgels (ANG 1- ANG 11) were prepared by emulsification and solvent evaporation method using flaxseed oil and xanthan gum in different ratios, as suggested by the Design-Expert software. A 2-factor-5-level design was employed with different responses including spreadability, extrudability, viscosity, and drug release after 1 h (h) and 24 h. Based on the Design-Expert software response, the optimized emulgel ANG 12 was formulated and evaluated. The 24 h In-vitro drug release was found to be 95.7 % following Higuchi kinetics. Ex-vivo skin retention of 784.78 ug/cm2 was observed during the study. MTT assay performed on Human epidermoid carcinoma (A-431) cells demonstrated cell growth arrest at G0/G1 and G2/M phase after 24 h of ANG 12 treatment (IC50: 11.5 µg/ml). The cellular permeability of ANG-12 was assessed by Fluorescein isothiocyanate (FITC) assay. Compared to untreated cells (0.54 % uptake) the ANG-12 treated cells had shown 87.17 % FITC permeation. The biocompatibility study performed on non-cancerous human dermal fibroblast cells (HDF cells) shows 91.54 % viability after 24 h of the treatment showing the non-toxic nature of ANG-12. Confocal imaging had shown a significant time-dependent increase in in-vivo cellular uptake with enhanced, progressive penetration of the emulgel into the skin. An in-vivo skin irritation study conducted on Swiss albino mice confirmed the safety aspects of the ANG 12. Hence, it can be concluded that nanoemulgel of andrographolide (ANG 12) could be a novel approach to treating skin cancer.

21 June 2023 in Gels
Verified
Journal Article
Open access
PDF file
NMN. V. L. Sirisha Mulukuri
N. V. L. Sirisha Mulukuri
MDMoumita College of Pharmaceutical Dhara
Moumita College of Pharmaceutical Dhara
GDGupta Dheeraj Dheeraj
Gupta Dheeraj Dheeraj
KDKusum Devi
Kusum Devi
PKPANKAJ KUMAR
PANKAJ KUMAR
An epidermoid carcinoma is a form of non-melanoma skin cancer that originates from the outer layer of the skin’s squamous cells. Previous studies have shown that andrographis extract and andrographolide inhibit the growth and proliferation of epidermoid carcinoma cells while also inducing cell cycle arrest and apoptosis. The objective of this study was to improve the anticancer efficacy of the andrographolide-rich extract by delivering it in the form of nanoemulgel. During the formulation of emulgels, sonication, and homogenization were employed, and a 22-factorial design was used to optimize the formulations through the quality by design (QbD) approach. The optimized formulation (AEE8) was subjected to preliminary evaluations along with particle size, drug release, and scanning electron microscopy (SEM) studies. The potential of the optimized emulgel against A431 cell lines was also investigated using MTT assay followed by flow cytometric analysis. The SEM results reveal that the optimized emulgel had a well-defined spherical shape, with a droplet size of 226 ± 1.8 nm, a negative surface charge of −30.1 ± 1.6 mV, and a PDI of 0.157. The cellular data indicate that AEE8 reduced the viability of the A431 cells with an IC50 of 16.56 μg/mL, as determined by MTT assay when compared to cells treated with the extract alone. Furthermore, the flow cytometric analysis of the optimized emulgel formulation demonstrated a marked G2/M phase arrest. This finding further supports the effectiveness of the gel in disrupting the cell cycle at the critical G2 and M phases, which are pivotal for cell division and proliferation. This disruption in cell cycle progression can impede the growth and spread of cancer cells, making the gel a promising candidate for anti-skin-cancer therapy. The safety of emulgels (AEE8) was validated through rigorous biocompatibility testing conducted on HDF (human dermal fibroblast) cell lines, ensuring their suitability for use. Considering the potential of the nanoemulgel, particularly AEE8, as demonstrated by its favorable properties and its ability to disrupt the cell cycle, it holds great promise as an innovative approach to treating skin cancer.